[Estrogen-progestin agents].
Cardio-vascular pathology with estroprogestatives have justified an evolution of oral contraceptives of which the essential steps are the decrease of the posology in ethinylestradiol and the adjustment of new progestatives. This has allowed a decrease of thromboembolic risk and an improvement in the metabolic tolerance. The author, after having established an inventory of the products which exist on the French market calls for the prescription and the supervision of an estroprogestative contraception as well as reminds a certain number of practical advices.